Page last updated: 2024-08-25

bendamustine hydrochloride and Cutaneous T-Cell Lymphoma

bendamustine hydrochloride has been researched along with Cutaneous T-Cell Lymphoma in 4 studies

Research

Studies (4)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	0 (0.00)	29.6817
2010's	2 (50.00)	24.3611
2020's	2 (50.00)	2.80

Authors

Authors	Studies
Assaf, C; Burmann, SN; Cerroni, L; Kreuter, A; Michalowitz, AL; Oellig, F	1
Assaf, C; Cerroni, L; Koushk-Jalali, B; Kreuter, A; Mitrakos, G; Oellig, F; Tigges, C	1
Bagot, M; Battistella, M; Bouaziz, JD; Brice, P; de Masson, A; Delyon, J; Dumont, M; Herms, F; Lebbé, C; Madelaine, I; Moins-Teisserenc, H; Peffault de Latour, R; Ram-Wolff, C; Roelens, M	1
Banos, A; Béné, MC; Bouabdallah, K; Bubenheim, M; Cartron, G; Choufi, B; Cony-Makhoul, P; Damaj, G; Diouf, M; Gressin, R; Gyan, E; Houot, R; Jaccard, A; Joly, B; Lamy, T; Le Gouill, S; Marolleau, JP; Martin, A; Park, S; Saad, A; Sanhes, L; Schiano-de Collela, JM; Schmidt-Tanguy, A; Tournilhac, O; Vilque, JP; Voillat, L	1

Trials

1 trial(s) available for bendamustine hydrochloride and Cutaneous T-Cell Lymphoma

Article	Year
Results from a prospective, open-label, phase II trial of bendamustine in refractory or relapsed T-cell lymphomas: the BENTLY trial. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2013, Jan-01, Volume: 31, Issue:1 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Bendamustine Hydrochloride; Drug Resistance, Neoplasm; Female; Follow-Up Studies; Humans; Lymphoma, T-Cell, Cutaneous; Lymphoma, T-Cell, Peripheral; Male; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Nitrogen Mustard Compounds; Prognosis; Prospective Studies; Remission Induction; Salvage Therapy; Survival Rate	2013

Article

Year

Results from a prospective, open-label, phase II trial of bendamustine in refractory or relapsed T-cell lymphomas: the BENTLY trial.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2013, Jan-01, Volume: 31, Issue:1

Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Bendamustine Hydrochloride; Drug Resistance, Neoplasm; Female; Follow-Up Studies; Humans; Lymphoma, T-Cell, Cutaneous; Lymphoma, T-Cell, Peripheral; Male; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Nitrogen Mustard Compounds; Prognosis; Prospective Studies; Remission Induction; Salvage Therapy; Survival Rate

2013

Other Studies

3 other study(ies) available for bendamustine hydrochloride and Cutaneous T-Cell Lymphoma

Article	Year
Bendamustine monochemotherapy in aggressive or advanced-stage primary cutaneous T-cell lymphomas. Journal of the European Academy of Dermatology and Venereology : JEADV, 2023, Volume: 37, Issue:2 Topics: Bendamustine Hydrochloride; Humans; Lymphoma, T-Cell, Cutaneous; Skin Neoplasms	2023
Bendamustine Monotherapy for Primary Cutaneous Gamma-Delta T-Cell Lymphoma. JAMA dermatology, 2020, 10-01, Volume: 156, Issue:10 Topics: Administration, Cutaneous; Bendamustine Hydrochloride; Biopsy; Chemotherapy, Adjuvant; Debridement; Drug Administration Schedule; Humans; Intraepithelial Lymphocytes; Lymphoma, T-Cell, Cutaneous; Magnetic Resonance Imaging; Male; Middle Aged; Necrosis; Neoplasm Staging; Receptors, Antigen, T-Cell, gamma-delta; Skin; Treatment Outcome	2020
Efficacy and safety of brentuximab vedotin plus bendamustine in advanced-stage primary cutaneous T-cell lymphomas. The British journal of dermatology, 2019, Volume: 181, Issue:6 Topics: Acute Kidney Injury; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Brentuximab Vedotin; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Humans; Lymphoma, T-Cell, Cutaneous; Male; Middle Aged; Neoplasm Staging; Pneumonia, Pneumocystis; Severity of Illness Index; Skin; Skin Neoplasms; Treatment Outcome	2019